Primer: Gamechangers in Alopecia Areata: Targeted Therapies for Patient-Centered Care

Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Additionally, studies have uncovered risk factors for AA that clinicians need to be aware of when treating either pediatric or adult patients.

 

This primer activity contains foundational information and clinical data regarding alopecia areata, including disease pathogenesis, relevant pathways, burden of disease and comorbidities, and new targets for treatment. This webcast will be briefly reviewed at the start of the live satellite symposium at the MOPD/SBS 2023 meeting (https://www.livderm.org/south-beach-symposium-2023/) and will serve to prime the attendees for the in-depth patient case simulation and expert discussion that will take place during the session.

 

Target Audience

These activities are designed for an audience of U.S. based dermatologists, pediatric dermatologists, nurses, nurse practitioners, and/or physician assistants who treat alopecia areata and other medical dermatology conditions.

 

Learning Objectives

  • Summarize the burden of disease for AA patients including psychosocial and medical comorbidities
  • Review signaling pathways involved in the pathogenesis of alopecia areata
  • Interpret clinical safety and efficacy data, as well as mechanisms of action, for emerging treatments of alopecia areata
  • Apply knowledge of new and emerging therapies for optimal patient selection and treatment plan design
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
01/23/2023
Course expires: 
01/24/2024
Rating: 
0
  • Introductory Overview of AA
  • Clinical Manifestation of AA
  • Current Treatments
  • Pathophysiology
  • Mechanism of Action Video
  • New and Emerging Therapeutic Options

Brittany G. Craiglow, MD

Brett A. King, MD, PhD

Natasha A. Mesinkovska, MD, PhD

 

 

Credit provided by AKH Inc., Advancing Knowledge in Healthcare


In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse

1.0 ANCC contact hour

Commercial Support
This activity is supported by an educational grant from Pfizer.

 

Disclosure 

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

 

Disclosures

NAME

RELATIONSHIP

COMPANY

Brittany G. Craiglow, MD

Consultant

Pfizer, Eli Lilly and Company, Concert Pharmaceuticals - alopecia areata; Regeneron, Sanofi Genzyme - atopic dermatitis

Speaker

Incyte - vitiligo; Regeneron, Sanofi Genzyme - atopic dermatitis

   

Brett A. King, MD, PhD

Advisor

Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio

Consultant

Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio

Individual stocks and stock options

BiologicsMD
   

Natasha A. Mesinkovska, MD, PhD

Consultant - Principal InvestigatorAbbvie, Arcutis, Arena, BMS, Concert, Galderma, Merz, Eli Lilly and Company, Kadmon, Novartis, Pfizer
Honoraria/FeesEli Lilly and Company, Nutrafol, Concert, Arena
   

LiVDerm Planners and Reviewers

N/A

Nothing to disclose

   

AKH Planners and Reviewers

N/A

Nothing to disclose

   

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.